AstraZeneca and Daiichi Sankyo continue to flesh out Enhertu plans, claiming win in earlier breast cancer line
AstraZeneca and Daiichi Sankyo have big plans for their blockbuster-in-the-making Enhertu, and the pair touted another win Monday morning in the quest to conquer the breast cancer market.
Enhertu reached its primary endpoint in a study looking at HER2-positive metastatic breast cancer patients who had previously been treated with one prior line of HER2-based therapy, the companies announced, demonstrating superiority in progression-free survival over Roche’s Kadcyla and chemo. Full data aren’t available yet, but Daiichi Sankyo noted the trial has been recommended for unblinding by the IMDC after reaching this interim analysis.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.